Bicycle Therapeutics downgraded by B. Riley Securities with a new price target

8/7/24 6:40:33 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

B. Riley Securities downgraded Bicycle Therapeutics from Buy to Neutral and set a new price target of $28.00 from $33.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BCYC

Date	Price Target	Rating	Analyst
11/8/2024	$25.00	Equal-Weight	Stephens
9/6/2024	$35.00	Outperform	RBC Capital Mkts
8/7/2024	$33.00 → $28.00	Buy → Neutral	B. Riley Securities
9/11/2023		Neutral → Buy	B. Riley Securities
8/31/2022		Outperform	Cowen
7/28/2022	$30.00	Overweight	Barclays
7/6/2022	$60.00	Buy	Canaccord Genuity
4/13/2022	$62.00 → $33.00	Buy → Neutral	B. Riley Securities